PT - JOURNAL ARTICLE AU - L. McAllan AU - D. Baranasic AU - S. Villicaña AU - W. Zhang AU - B. Lehne AU - M. Adamo AU - A. Jenkinson AU - M. Elkalaawy AU - B. Mohammadi AU - M. Hashemi AU - Y. Yang AU - L. Zudina AU - V. Lagou AU - S. Tan AU - J. Castillo-Fernandez AU - R. Soong AU - P. Elliott AU - J. Scott AU - M. Loh AU - I. Prokopenko AU - B. Lenhard AU - R. L. Batterham AU - J. Bell AU - J. Chambers AU - J. Kooner AU - W. Scott TI - Integrative genomic analyses in adipocytes implicate DNA methylation in human obesity and diabetes AID - 10.1101/2021.12.20.21266893 DP - 2022 Jan 01 TA - medRxiv PG - 2021.12.20.21266893 4099 - http://medrxiv.org/content/early/2022/10/24/2021.12.20.21266893.short 4100 - http://medrxiv.org/content/early/2022/10/24/2021.12.20.21266893.full AB - DNA methylation variations are prevalent in human obesity, but evidence of a causative role in disease pathogenesis is limited. In this study, we combine epigenome-wide association and integrative genomics to investigate the impact of subcutaneous and visceral adipocyte DNA methylation variations in extreme human obesity. We identify extensive DNA methylation changes that are robustly associated with extreme obesity in combined discovery and replication analyses (N=190 samples, 691 loci in subcutaneous and 173 loci in visceral adipocytes, P<1×10-7). Using functional interaction maps and methylation-expression association testing in human adipocytes, we connect extreme obesity-associated methylation variations to transcriptomic changes at >500 target genes. We find that disease-associated methylation variations localise to active genomic regions and transcription factor binding sites, at which DNA methylation influences transcription factor-target gene co-expression relationships. In Mendelian Randomisation analyses, we infer causal effects of DNA methylation on human obesity and obesity-induced metabolic disturbances, under genetic control, at 28 independent loci. Silencing of two target genes of causal DNA methylation variations, the PRRC2A and LIMD2 genes, further reveals novel metabolic effects in adipocytes. Our results indicate DNA methylation is an important determinant of human obesity and its metabolic complications, and reveal genomic and molecular mechanisms through which altered DNA methylation may impact adipocyte cellular functions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Medical Research Council UK (MR/K002414/1), the Wellcome Trust (219602/Z/19/Z) and the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). The Illumina HumanMethylation450 Beadchip data used in this research was generated by the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z). The Illumina EPIC Beadchip data were generated in collaboration with RS. The NIHR Imperial BRC Genomics Facility provided resources and support that contributed to the reported RNA sequencing results. The TwinsUK research components were funded by JPI ERA-HDHL DIMENSION via the Biotechnology and Biological Sciences Research Council (BB/S020845/1). TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the NIHR-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust in partnership with Kings College London. We thank the participants and research staff who made this possible.  Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The London - City Road & Hampstead Research Ethics Committee United Kingdom (reference 13/LO/0477) approved this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors, and will be made openly available after critical review.